Efficacy of methotrexate treatment in viable and nonviable cervical pregnancies

Objectives: This retrospective study examined the overall efficacy of methotrexate chemotherapy in the treatment of cervical pregnancy and attempted to determine whether differences in the response to methotrexate therapy exist between patients with viable and nonviable cervical pregnancies. Study D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of obstetrics and gynecology 1999-12, Vol.181 (6), p.1438-1444
Hauptverfasser: Kung, Fu-Tsai, Chang, Shiuh-Young
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1444
container_issue 6
container_start_page 1438
container_title American journal of obstetrics and gynecology
container_volume 181
creator Kung, Fu-Tsai
Chang, Shiuh-Young
description Objectives: This retrospective study examined the overall efficacy of methotrexate chemotherapy in the treatment of cervical pregnancy and attempted to determine whether differences in the response to methotrexate therapy exist between patients with viable and nonviable cervical pregnancies. Study Design: A MEDLINE database search and a bibliographic review of the relevant literature were conducted to find reported cases of cervical pregnancy treated with methotrexate administration during the period from 1983 to 1997. Clinical and demographic characteristics, methotrexate regimen, concomitant invasive procedures, complications, and outcomes in viable and nonviable pregnancy groups were analyzed and compared. Results: A total of 62 reported cases of cervical pregnancy were assessed. There were no statistically significant differences in demographic data, transfusion rate, and human chorionic gonadotropin remission time between viable and nonviable cervical pregnancy groups. Among the 35 cases of viable pregnancy 63% of women received systemic injection alone or a combination of systemic and local (intra-amniotic or intracervical) injection with methotrexate or potassium chloride and 37% had local injection of methotrexate (with or without potassium chloride) alone. Among the 23 cases of nonviable cervical pregnancy 96% of women received systemic methotrexate injection only. The need for ≥1 concomitant surgical procedure (such as simple curettage, dilation and curettage, cervical blocking, or uterine artery embolization) in conjunction with methotrexate therapy was significantly higher (P = .021) in the viable pregnancy group (43%) than in the nonviable pregnancy group (13%). The 94% success rate of preservation of the uterus in the viable pregnancy group was not significantly different from the 91% preservation rate in the nonviable pregnancy group. All patients who had successful uterine preservation returned to normal menstrual patterns. Conclusion: This retrospective study found that conservative treatment with methotrexate chemotherapy of patients with either viable or nonviable cervical pregnancies at
doi_str_mv 10.1016/S0002-9378(99)70389-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69367851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002937899703893</els_id><sourcerecordid>69367851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-a545a95006aec76924e9a4b926ee255fb48a44784e3c267c333339be3d695d163</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMouq7-BKUHET1U89GkyUlk8QsED-o5pOlUI226Jt1F_72pu6g35zIMPO_M8CB0QPAZwUScP2KMaa5YKU-UOi0xkypnG2hCsCpzIYXcRJMfZAftxvg2jlTRbbRDsMBEUTFBD1dN46yxn1nfZB0Mr_0Q4MMMkKVuhg78kDmfLZ2pWsiMrzPf-_VkISxTts3mAV688dZB3ENbjWkj7K_7FD1fXz3NbvP7h5u72eV9bjmWQ254wY3iGAsDthSKFqBMUaWXACjnTVVIUxSlLIBZKkrLxlIVsFooXhPBpuh4tXce-vcFxEF3LlpoW-OhX0QtFBOl5CSBfAXa0McYoNHz4DoTPjXBejSpv03qUZNWSn-b1CzlDtcHFlUH9Z_USl0CjtaAiUlCE0YB8ZejhEo67rlYYZBsLB0EHZMnb6F2Aeyg697988kXLSePeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69367851</pqid></control><display><type>article</type><title>Efficacy of methotrexate treatment in viable and nonviable cervical pregnancies</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kung, Fu-Tsai ; Chang, Shiuh-Young</creator><creatorcontrib>Kung, Fu-Tsai ; Chang, Shiuh-Young</creatorcontrib><description>Objectives: This retrospective study examined the overall efficacy of methotrexate chemotherapy in the treatment of cervical pregnancy and attempted to determine whether differences in the response to methotrexate therapy exist between patients with viable and nonviable cervical pregnancies. Study Design: A MEDLINE database search and a bibliographic review of the relevant literature were conducted to find reported cases of cervical pregnancy treated with methotrexate administration during the period from 1983 to 1997. Clinical and demographic characteristics, methotrexate regimen, concomitant invasive procedures, complications, and outcomes in viable and nonviable pregnancy groups were analyzed and compared. Results: A total of 62 reported cases of cervical pregnancy were assessed. There were no statistically significant differences in demographic data, transfusion rate, and human chorionic gonadotropin remission time between viable and nonviable cervical pregnancy groups. Among the 35 cases of viable pregnancy 63% of women received systemic injection alone or a combination of systemic and local (intra-amniotic or intracervical) injection with methotrexate or potassium chloride and 37% had local injection of methotrexate (with or without potassium chloride) alone. Among the 23 cases of nonviable cervical pregnancy 96% of women received systemic methotrexate injection only. The need for ≥1 concomitant surgical procedure (such as simple curettage, dilation and curettage, cervical blocking, or uterine artery embolization) in conjunction with methotrexate therapy was significantly higher (P = .021) in the viable pregnancy group (43%) than in the nonviable pregnancy group (13%). The 94% success rate of preservation of the uterus in the viable pregnancy group was not significantly different from the 91% preservation rate in the nonviable pregnancy group. All patients who had successful uterine preservation returned to normal menstrual patterns. Conclusion: This retrospective study found that conservative treatment with methotrexate chemotherapy of patients with either viable or nonviable cervical pregnancies at &lt;12 weeks’ gestation carries a 91% success rate for preservation of the uterus. The structure of the cervix was restored and menstruation returned for all patients in whom the uterus was preserved after treatment. There was no evidence to suggest that the reproductive performance of these patients was affected by the treatment. (Am J Obstet Gynecol 1999;181:1438-44.)</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/S0002-9378(99)70389-3</identifier><identifier>PMID: 10601926</identifier><identifier>CODEN: AJOGAH</identifier><language>eng</language><publisher>Philadelphia, PA: Mosby, Inc</publisher><subject>Abortifacient Agents, Nonsteroidal - therapeutic use ; Abortion, Therapeutic - methods ; Adult ; Biological and medical sciences ; Cervical pregnancy ; Cervix Uteri ; Female ; Fetal Viability ; Genital system. Reproduction ; Humans ; Medical sciences ; methotrexate ; Methotrexate - therapeutic use ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy, Ectopic - drug therapy ; Retrospective Studies ; Treatment Outcome ; Tropical medicine</subject><ispartof>American journal of obstetrics and gynecology, 1999-12, Vol.181 (6), p.1438-1444</ispartof><rights>1999 Mosby, Inc.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-a545a95006aec76924e9a4b926ee255fb48a44784e3c267c333339be3d695d163</citedby><cites>FETCH-LOGICAL-c508t-a545a95006aec76924e9a4b926ee255fb48a44784e3c267c333339be3d695d163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9378(99)70389-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1212823$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10601926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kung, Fu-Tsai</creatorcontrib><creatorcontrib>Chang, Shiuh-Young</creatorcontrib><title>Efficacy of methotrexate treatment in viable and nonviable cervical pregnancies</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>Objectives: This retrospective study examined the overall efficacy of methotrexate chemotherapy in the treatment of cervical pregnancy and attempted to determine whether differences in the response to methotrexate therapy exist between patients with viable and nonviable cervical pregnancies. Study Design: A MEDLINE database search and a bibliographic review of the relevant literature were conducted to find reported cases of cervical pregnancy treated with methotrexate administration during the period from 1983 to 1997. Clinical and demographic characteristics, methotrexate regimen, concomitant invasive procedures, complications, and outcomes in viable and nonviable pregnancy groups were analyzed and compared. Results: A total of 62 reported cases of cervical pregnancy were assessed. There were no statistically significant differences in demographic data, transfusion rate, and human chorionic gonadotropin remission time between viable and nonviable cervical pregnancy groups. Among the 35 cases of viable pregnancy 63% of women received systemic injection alone or a combination of systemic and local (intra-amniotic or intracervical) injection with methotrexate or potassium chloride and 37% had local injection of methotrexate (with or without potassium chloride) alone. Among the 23 cases of nonviable cervical pregnancy 96% of women received systemic methotrexate injection only. The need for ≥1 concomitant surgical procedure (such as simple curettage, dilation and curettage, cervical blocking, or uterine artery embolization) in conjunction with methotrexate therapy was significantly higher (P = .021) in the viable pregnancy group (43%) than in the nonviable pregnancy group (13%). The 94% success rate of preservation of the uterus in the viable pregnancy group was not significantly different from the 91% preservation rate in the nonviable pregnancy group. All patients who had successful uterine preservation returned to normal menstrual patterns. Conclusion: This retrospective study found that conservative treatment with methotrexate chemotherapy of patients with either viable or nonviable cervical pregnancies at &lt;12 weeks’ gestation carries a 91% success rate for preservation of the uterus. The structure of the cervix was restored and menstruation returned for all patients in whom the uterus was preserved after treatment. There was no evidence to suggest that the reproductive performance of these patients was affected by the treatment. (Am J Obstet Gynecol 1999;181:1438-44.)</description><subject>Abortifacient Agents, Nonsteroidal - therapeutic use</subject><subject>Abortion, Therapeutic - methods</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cervical pregnancy</subject><subject>Cervix Uteri</subject><subject>Female</subject><subject>Fetal Viability</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>methotrexate</subject><subject>Methotrexate - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy, Ectopic - drug therapy</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Tropical medicine</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMouq7-BKUHET1U89GkyUlk8QsED-o5pOlUI226Jt1F_72pu6g35zIMPO_M8CB0QPAZwUScP2KMaa5YKU-UOi0xkypnG2hCsCpzIYXcRJMfZAftxvg2jlTRbbRDsMBEUTFBD1dN46yxn1nfZB0Mr_0Q4MMMkKVuhg78kDmfLZ2pWsiMrzPf-_VkISxTts3mAV688dZB3ENbjWkj7K_7FD1fXz3NbvP7h5u72eV9bjmWQ254wY3iGAsDthSKFqBMUaWXACjnTVVIUxSlLIBZKkrLxlIVsFooXhPBpuh4tXce-vcFxEF3LlpoW-OhX0QtFBOl5CSBfAXa0McYoNHz4DoTPjXBejSpv03qUZNWSn-b1CzlDtcHFlUH9Z_USl0CjtaAiUlCE0YB8ZejhEo67rlYYZBsLB0EHZMnb6F2Aeyg697988kXLSePeQ</recordid><startdate>19991201</startdate><enddate>19991201</enddate><creator>Kung, Fu-Tsai</creator><creator>Chang, Shiuh-Young</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991201</creationdate><title>Efficacy of methotrexate treatment in viable and nonviable cervical pregnancies</title><author>Kung, Fu-Tsai ; Chang, Shiuh-Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-a545a95006aec76924e9a4b926ee255fb48a44784e3c267c333339be3d695d163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Abortifacient Agents, Nonsteroidal - therapeutic use</topic><topic>Abortion, Therapeutic - methods</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cervical pregnancy</topic><topic>Cervix Uteri</topic><topic>Female</topic><topic>Fetal Viability</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>methotrexate</topic><topic>Methotrexate - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy, Ectopic - drug therapy</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Tropical medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kung, Fu-Tsai</creatorcontrib><creatorcontrib>Chang, Shiuh-Young</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kung, Fu-Tsai</au><au>Chang, Shiuh-Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of methotrexate treatment in viable and nonviable cervical pregnancies</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>1999-12-01</date><risdate>1999</risdate><volume>181</volume><issue>6</issue><spage>1438</spage><epage>1444</epage><pages>1438-1444</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><coden>AJOGAH</coden><abstract>Objectives: This retrospective study examined the overall efficacy of methotrexate chemotherapy in the treatment of cervical pregnancy and attempted to determine whether differences in the response to methotrexate therapy exist between patients with viable and nonviable cervical pregnancies. Study Design: A MEDLINE database search and a bibliographic review of the relevant literature were conducted to find reported cases of cervical pregnancy treated with methotrexate administration during the period from 1983 to 1997. Clinical and demographic characteristics, methotrexate regimen, concomitant invasive procedures, complications, and outcomes in viable and nonviable pregnancy groups were analyzed and compared. Results: A total of 62 reported cases of cervical pregnancy were assessed. There were no statistically significant differences in demographic data, transfusion rate, and human chorionic gonadotropin remission time between viable and nonviable cervical pregnancy groups. Among the 35 cases of viable pregnancy 63% of women received systemic injection alone or a combination of systemic and local (intra-amniotic or intracervical) injection with methotrexate or potassium chloride and 37% had local injection of methotrexate (with or without potassium chloride) alone. Among the 23 cases of nonviable cervical pregnancy 96% of women received systemic methotrexate injection only. The need for ≥1 concomitant surgical procedure (such as simple curettage, dilation and curettage, cervical blocking, or uterine artery embolization) in conjunction with methotrexate therapy was significantly higher (P = .021) in the viable pregnancy group (43%) than in the nonviable pregnancy group (13%). The 94% success rate of preservation of the uterus in the viable pregnancy group was not significantly different from the 91% preservation rate in the nonviable pregnancy group. All patients who had successful uterine preservation returned to normal menstrual patterns. Conclusion: This retrospective study found that conservative treatment with methotrexate chemotherapy of patients with either viable or nonviable cervical pregnancies at &lt;12 weeks’ gestation carries a 91% success rate for preservation of the uterus. The structure of the cervix was restored and menstruation returned for all patients in whom the uterus was preserved after treatment. There was no evidence to suggest that the reproductive performance of these patients was affected by the treatment. (Am J Obstet Gynecol 1999;181:1438-44.)</abstract><cop>Philadelphia, PA</cop><pub>Mosby, Inc</pub><pmid>10601926</pmid><doi>10.1016/S0002-9378(99)70389-3</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9378
ispartof American journal of obstetrics and gynecology, 1999-12, Vol.181 (6), p.1438-1444
issn 0002-9378
1097-6868
language eng
recordid cdi_proquest_miscellaneous_69367851
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Abortifacient Agents, Nonsteroidal - therapeutic use
Abortion, Therapeutic - methods
Adult
Biological and medical sciences
Cervical pregnancy
Cervix Uteri
Female
Fetal Viability
Genital system. Reproduction
Humans
Medical sciences
methotrexate
Methotrexate - therapeutic use
Pharmacology. Drug treatments
Pregnancy
Pregnancy, Ectopic - drug therapy
Retrospective Studies
Treatment Outcome
Tropical medicine
title Efficacy of methotrexate treatment in viable and nonviable cervical pregnancies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A00%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20methotrexate%20treatment%20in%20viable%20and%20nonviable%20cervical%20pregnancies&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Kung,%20Fu-Tsai&rft.date=1999-12-01&rft.volume=181&rft.issue=6&rft.spage=1438&rft.epage=1444&rft.pages=1438-1444&rft.issn=0002-9378&rft.eissn=1097-6868&rft.coden=AJOGAH&rft_id=info:doi/10.1016/S0002-9378(99)70389-3&rft_dat=%3Cproquest_cross%3E69367851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69367851&rft_id=info:pmid/10601926&rft_els_id=S0002937899703893&rfr_iscdi=true